Interruption of functional recovery by the NMDA glutamate antagonist MK801 after compression of the sensorimotor cortex: Implications for treatment of tumors or other mass-related brain injuries

Experimental Neurology

Volumn 200, Issue 1, 2006, Pages 262-266

  Yang, Hongyan ^a   Chopp, Michael ^c,d   Jiang, Feng ^c   Zhang, Xuepeng ^c   Schallert, Timothy ^a,b,c  

^a UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c HENRY FORD HOSPITAL   (United States)

^d OAKLAND UNIVERSITY   (United States)

Author keywords

Brain tumor; Glutamate antagonist; Injury; MK801; Neuroplasticity; Quality of life; Sensorimotor cortex

Indexed keywords

DIZOCILPINE; GLUTAMATE RECEPTOR ANTAGONIST; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN FUNCTION; BRAIN INJURY; BRAIN TUMOR; COMPRESSION THERAPY; CONTROLLED STUDY; CONVALESCENCE; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SENSORIMOTOR CORTEX;

ANIMALS; BRAIN INJURIES; BRAIN NEOPLASMS; DIZOCILPINE MALEATE; DRUG EVALUATION, PRECLINICAL; EXCITATORY AMINO ACID ANTAGONISTS; MALE; MOTOR CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, N-METHYL-D-ASPARTATE; RECOVERY OF FUNCTION; SOMATOSENSORY CORTEX;

EID: 33646560739     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1562/2005-06-21-RA-587     Document Type: Article

References (33)

1. Barth T.M., Grant M.L., and Schallert T. Effects of MK-801 on recovery from sensorimotor cortex lesions. Stroke 21 Suppl 11 (1990) III153-III157
2. Barth T.M., Hoane M.R., and Barbay S. Effects of glutamate antagonists on the recovery and maintenance of behavioral functions after brain injury. In: Goldstein L.B. (Ed). Restorative Neurology Advances in Pharmacotherapy for Recovery after Stroke (1998), Futura Publishing Co Inc, Armonk, NY 121-140
3. Benveniste H., Drejer J., Schousboe A., and Diemer N.H. Elevation of the extracellular concentrations of glutamate in rat hippocampus during transient cerebral ischaemia monitored by intracerebral microdialysis. J. Neurochem. 43 (1984) 1369-1374
4. Biegon A., Fry P.A., Paden C.M., Alexandrovich A., Tsenter J., and Shohami E. Dynamic changes in N-methyl-d-aspartate receptors after closed head injury in mice: implications for treatment of neurological and cognitive deficits. Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 5117-5122
5. Butcher S., Bullock R., Graham D.I., and McCulloch J. Correlation between amino acid release and neuropathologic outcome in rat brain following middle cerebral artery occlusion. Stroke 21 (1990) 1727-1733
6. Chen J.R., Wang Y.J., and Tseng G.F. The effect of epidural compression on cerebral cortex: a rat model. J. Neurotrauma 20 (2003) 767-780
7. Chen J.R., Wang Y.J., and Tseng G.F. The effects of decompression and exogenous NGF on compressed cerebral cortex. J. Neurotrauma 21 (2004) 1640-1651
8. Chung W.J., Lyons S.A., Nelson G.M., Hamza H., Gladson C.L., Gillespie G.Y., and Sontheimer H. Inhibition of cystine uptake disrupts the growth of primary brain tumors. J. Neurosci. 25 (2005) 7101-7110
9. Doble A. The role of excitotoxicity in neurodegenerative disease: implications for therapy. Pharmacol. Ther. 81 (1999) 163-221
10. Faden A.I., Demediuk P., Panter S.S., and Vink R. The role of excitatory amino acids and NMDA receptors in traumatic brain injury. Science 244 (1989) 799-800
11. Felt B.T., Schallert T., Shao J., Liu Y., Li X., and Barks J.D. Early appearance of functional deficits after neonatal excitotoxic and hypoxic-ischemic injury: fragile recovery after development and role of the NMDA receptor. Dev. Neurosci. 24 (2002) 418-425
12. Ikonomidou C., Bosch F., Miksa M., Bittigau P., Vockler J., Dikranian K., Tenkova T.I., Stefovska V., Turski L., and Olney J.W. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 283 (1999) 70-74
13. Ikonomidou C., Stefovska V., and Turski L. Neuronal death enhanced by N-methyl-d-aspartate antagonists. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 12885-12890
14. Ishiuchi S., Tsuzuki K., Yoshida Y., Yamada N., Hagimura N., Okado H., Miwa A., Kurihara H., Nakazato Y., Tamura M., Sasaki T., and Ozawa S. Blockage of Ca(2+)-permeable AMPA receptors suppresses migration and induces apoptosis in human glioblastoma cells. Nat. Med. 8 (2002) 971-978
15. Kozlowski D.A., and Schallert T. Relationship between dendritic pruning and behavioral recovery following sensorimotor cortex lesions. Behav. Brain Res. 97 (1998) 89-98
16. Kozlowski D.A., Jones T.A., and Schallert T. Pruning of dendrites and restoration of function after brain damage: role of the NMDA receptor. Rest. Neurol. Neurosci. 7 (1994) 119-126
17. Kozlowski D.A., Hilliard S., and Schallert T. Ethanol consumption following recovery from unilateral damage to the forelimb area of the sensorimotor cortex: reinstatement of deficits and prevention of dendritic pruning. Brain Res. 763 (1997) 159-166
18. Kundrotiene J., Cebers G., Wagner A., and Liljequist S. The NMDA NR2B subunit-selective receptor antagonist, CP-101,606, enhances the functional recovery the NMDA NR2B subunit-selective receptor and reduces brain damage after cortical compression-induced brain ischemia. J. Neurotrauma 21 (2004) 83-93
19. Miguel-Hidalgo J.J., Alvarez X.A., Cacabelos R., and Quack G. Neuroprotection by memantine against neurodegeneration induced by beta-amyloid (1-40). Brain Res. 958 (2002) 210-221
20. Olney J.W., Zorumski C.F., Stewart G.R., Price M.T., Wang G.J., and Labruyere J. Excitotoxicity of l-dopa and 6-OH-dopa: implications for Parkinson's and Huntington's diseases. Exp. Neurol. 108 (1990) 269-272
21. Olney J.W., Tenkova T., Dikranian K., Qin Y.Q., Labruyere J., and Ikonomidou C. Ethanol-induced apoptotic neurodegeneration in the developing C57BL/6 mouse brain. Brain Res. Dev. Brain Res. 133 (2002) 115-126
22. Parsons C.G., Danysz W., and Quack G. Memantine is a clinically well tolerated N-methyl-d-aspartate (NMDA) receptor antagonist-A review of preclinical data. Neuropharmacology 38 (1999) 735-767
23. Planells-Cases R., Montoliu C., Humet M., Fernandez A.M., Garcia-Martinez C., Valera E., Merino J.M., Perez-Paya E., Messeguer A., Felipo V., and Ferrer-Montiel A. A novel N-methyl-d-aspartate receptor open channel blocker with in vivo neuroprotectant activity. J. Pharmacol. Exp. Ther. 302 (2002) 163-173
24. Rzeski W., Turski L., and Ikonomidou C. Glutamate antagonists limit tumor growth. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 6372-6377
25. Schallert T., and Woodlee M.T. Motor systems: orienting and placing. In: Whishaw I.Q., and Kolb B. (Eds). The Behavior of the Laboratory Rat: A Hand Book with Tests (2005), Oxford University Press, NY 129-140
26. Schallert T., Fleming S.M., Leasure J.L., Tillerson J.L., and Bland S.T. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39 (2000) 777-787
27. Schallert T., Woodlee M.T., and Fleming S.M. Disentangling multiple types of recovery from brain injury. In: Krieglstein J., and Klumpp S. (Eds). Pharmacology of Cerebral Ischemia 2002 (2002), Medpharm Scientific Publishers, Stuttgart 201-216
28. Sontheimer H. Malignant gliomas: perverting glutamate and ion homeostasis for selective advantage. Trends Neurosci. 26 (2003) 543-549
29. Sun F.Y., and Faden A.I. Pretreatment with antisense oligodeoxynucleotides directed against the NMDA-R1 receptor enhances survival and behavioral recovery following traumatic brain injury in rats. Brain Res. 693 (1995) 163-168
30. Takano T., Lin J.H., Arcuino G., Gao Q., Yang J., and Nedergaard M. Glutamate release promotes growth of malignant gliomas. Nat. Med. 7 (2001) 1010-1015
31. Woodlee M.T., Asseo-Garcia A.M., Zhao X., Liu S.J., Jones T.A., and Schallert T. Testing forelimb placing "across the midline" reveals distinct, lesion-dependent patterns of recovery in rats. Exp. Neurol. 191 (2005) 310-317
32. Yang, H., Preston, M., Chopp, M., Jiang, F., Zhang, X., Schallert, T., in press. Mass-related traumatic tissue displacement and behavior: a screen for treatments that reduce harm to bystander cells and recovery of function. J. Neurotrauma.
33. Ye Z.C., and Sontheimer H. Glioma cells release excitotoxic concentrations of glutamate. Cancer Res. 59 (1999) 4383-4391